Project profile — Combatting Antimicrobial Resistance

• Africa, regional (33.30%)
• America, regional (33.30%)
• Asia, regional (33.40%)

• Health, General: Health policy and administrative management (12110) (50.00%)
• Basic Health: Infectious disease control (12250) (50.00%)

• Gender equality (not targeted)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• ICT as a tool for development (not targeted)

This project aims to decrease the impact of antimicrobial resistance (AMR), particularly in low- and middle-income countries. Interventions take place across the first four objectives of the Global Action Plan on AMR, which focus on increasing awareness of AMR as a public health threat; improving capacity to monitor AMR patterns, consumption and use; strengthening capacity in infection prevention and control; and strengthening systems to optimize use of antibiotics. The project also includes a component that reinforces linkages to combat AMR across the World Health Organization, with Member States and partners. The Public Health Agency of Canada is a technical partner in this project.

The expected intermediate outcomes of this project include: (1) enhanced coordination and evidence-based policy-making and planning among national and international actors; and (2) enhanced responsible and effective use of antibiotics at hospital and community level in selected low- and middle-income countries.

Results achieved by WHO through the support of the Government of Canada and other international donors in 2017-2018 include: (1) strengthened health systems in low- and middle-income countries through the development of national action plans (NAPs) on antimicrobial resistance (AMR) and improvements in the prevention and treatment of infectious diseases; (2) improved data collection on and knowledge around the use of antimicrobial drugs to inform policy and practice and implement NAPs; and (3) strengthened global AMR surveillance systems to guide appropriate action on the consumption, use, quality and safety of medicines to ensure the ability to treat and prevent infectious diseases.

• Proactive disclosure